A groundbreaking discovery has unveiled a new layer of complexity in the intricate world of cellular processes. Imagine DNA as a bustling railway, with its tracks made up of the four fundamental building blocks of DNA, always paired together. On this railway, two types of 'trains' are constantly on the move: one train copies the DNA, allowing cells to divide, while the other reads the DNA and creates mRNA, a blueprint for the proteins the cell needs.
A Traffic Controller on the DNA Railway
Enter the CFAP20 protein, a newly identified 'traffic controller' on this DNA railway. Without it, chaos reigns, potentially leading to the development of cancer. This finding, published in the esteemed journal Nature, has revolutionized our understanding of cellular mechanics.
Professor Martijn Luijsterburg explains, "The trains, or polymerases, travel at an incredible pace, covering thousands of base pairs per minute. They can meet within minutes, and often, things go awry at the beginning of a gene. The transcription train starts slowly, while the replication train behind it is already speeding along."
The CFAP20 protein acts as a regulator, ensuring the transcription train speeds up to avoid a collision from behind. Without CFAP20, the traffic comes to a halt. The transcription train stops, blocking the track, and the replication train crashes into it, unable to pass.
Luijsterburg adds, "The replication trains set off simultaneously at thousands of locations on the DNA. Without CFAP20, half of them stop, while the other half become stressed and try to compensate by speeding up. It's like trying to transcribe a book at lightning speed - you're bound to miss lines. The result is a flawed copy."
The Importance of Fundamental Research
Researcher Sidrit Uruci emphasizes the significance of this discovery, stating, "These flawed copies can lead to uncontrolled cell division or cells following the wrong instructions, which, over time, can result in cancer."
Uruci, Luijsterburg, and their colleagues are the first to uncover CFAP20's crucial role as a traffic controller. While this discovery may not immediately lead to treatments, Luijsterburg believes it lays the foundation for future advancements. "If we didn't invest in fundamental research, we'd never make such groundbreaking discoveries. And without these insights, we couldn't translate them into clinical practice and benefit patients. That's why conducting both fundamental research and translating it to practice is vital at the LUMC."
A New World of Possibilities
The CFAP20 study opens up a new realm of exploration for researchers. For cancer biologists, it provides an additional understanding of why cells go awry and cancer develops. For drug developers, CFAP20 presents a new target, as tumor cells appear to rely on it for faster division, even at the cost of DNA quality. "In the future, this could potentially be a weak spot we can exploit to combat tumor cells," Uruci suggests.
For fundamental researchers, this study serves as a reminder of the value in exploring unknown genes and proteins. "The human genome consists of 20,000 genes, yet 99% of studies focus on just 10%. Who knows what treasures we might uncover in the remaining 99%?"
This research was made possible through funding from an ERC Consolidator Grant and a Dutch Research Council Vici grant.
